Fog Pharmaceuticals

Fog Pharmaceuticals

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.fogpharma.com

Last Round

Series E

3/1/2024

Total Funding Raised

$496M

Company Overview

FogPharma is a biotechnology company that develops cell-penetrating mini proteins (CPMPs) aimed at targeting and neutralizing cancer-causing proteins within cancer cells, offering a novel approach to treating cancer-related diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Infrastructure

Keywords

Helicon peptide platformpeptide therapeuticsAI drug discoveryundruggable targetsβ-catenin inhibitorcell-penetrating peptidesFOG-001oncology therapeuticsWnt pathway inhibitorsprotein-protein interaction inhibitorsAI biotechdrug discovery platformtargeted radiopharmaceuticalsα-radioligand therapeuticssolid tumor treatmentParabilis MedicinesFog Pharmaceuticals

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Fog Pharmaceuticals Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Fog Pharmaceuticals Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series E3/1/2024
Series D11/21/2022
Series C3/1/2021
Series B5/16/2018

Fog Pharmaceuticals Investors

Notable investors and investment history

InvestorRounds
Deerfield ManagementSeries C, Seed, Series A, Series B, Series D
Horizons VenturesSeries B
Boyu CapitalSeed, Series A, Series B
RA Capital ManagementSeries E
Farallon Capital ManagementSeries C, Series E, Series D
Sixty Degree CapitalSeries E
GVSeries C, Series E, Series B, Series D

Fog Pharmaceuticals Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Fog Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Fog Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Year Founded2015
Last Funding3/1/2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







DisclaimerAll investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.